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Introduction

Results

Results

Tacrolimus (TAC) has been a mainstay of immunosuppressive therapy
following pediatric renal transplantation. TAC has a narrow therapeutic index,
thus, frequent therapeutic drug monitoring is employed to maximize efficacy
and avoid toxicity. Dose adjustments based on TAC trough levels are
challenging, since the drug displays complex pharmacokinetic behavior that
is affected by a multitude of genetic, physiologic and environmental factors.

Table 1. Published model covariates shown to significantly affect TAC exposure (and oral
clearance, Cl/F) in pediatric renal transplant recipients. Six pediatric popPK models from 4
studies were identified. All models reported that TAC pharmacokinetics was best described by a 2compartment structural model with first-order absorption preceded by a lag time, and elimination
from the central compartment. The most commonly identified covariates were allometrically scaled
body weight and CYP3A5 genotype. “X” denotes that covariate was included in the popPK model;
Gamma GT, gamma glutamyltransferase enzyme.

Figure 3. Bias and precision of each popPK model. Four models underpredicted measured
TAC levels (negative MRE), and two overpredicted measured TAC levels (positive MRE). A high
degree of variability between population predicted and measured TAC levels was noted for all
models. Boxplots represent ratios of each predicted-to-observed concentration pair, with blue
horizontal line indicating a ratio of 1. M4 is considered having the best predictive performance.
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Objective
With the goal of developing a clinician-driven TAC pharmacokinetic dosing
tool, our initial objectives were 1) to examine whether published TAC
population pharmacokinetic (popPK) models could serve as a foundation for
the dosing tool, and 2) evaluate their performance predicting TAC
concentrations in an independent cohort of Children’s Mercy (CM) patients.

Methods

• Model structure and
error
• PK parameter typical
values and covariates
(i.e., for Cl/F, Vc/F, Vp/F,
Q/F, ka)

Pharmacokinetics
of TAC in CMH
cohort

Evaluation of
model predictive
performance

• Retrospective
analysis of previously
measured TAC trough
levels, patient-related
and therapy-related
data

• Prediction-based
diagnostics
• Simulation-based
diagnostics
(ongoing)

Pharmacokinetic data analysis. From the collected publications, we extracted estimated
model parameters (i.e., thetas) and covariates that were identified to significantly affect TAC
levels. Population clearances, volumes of distribution and absorption rate constants were
then modelled for the CM cohort. For each observed post-transplant TAC concentration
(Cobs), population predicted concentration (Cpred) was estimated.
Estimation of bias via mean residual error (MRE):
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Figure 1. Analysis workflow.
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Figure 4. M4predicted versus
observed TAC
concentrations. Data
scatter is present on
both sides of the blue
line of identity,
although it appears
non-symmetrical. One
outlier (Cpred = 62.8
ng/mL, Cobs = 10.6
ng/mL) was omitted for
better visualization of
the rest of the data.

Figure 2. Variability in tacrolimus (TAC) trough blood concentrations in the first year
following kidney transplantation. Fifty-eight children (age 1-20 years) who were enrolled in
TAC pharmacokinetics study at CM had their TAC trough levels measured as a part of
routine clinical care. A total of 3809 samples (average 66 per subject) were collected. Blue
lines represent the upper and lower limit of targeted therapeutic interval at a given period
post-transplantation.

Conclusions
Four popPK models predicted TAC trough levels sufficiently well on average, however
none of the evaluated models predicted TAC levels with high precision. This suggests
that variability in measured TAC levels cannot entirely be explained by the covariates
nested in established models. Development of a reliable and accurate dosing tool will
require significant refinement of existing models or the creation of a de novo model.
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